AU2020245480A1 - PRMT5 inhibitors and uses thereof - Google Patents

PRMT5 inhibitors and uses thereof Download PDF

Info

Publication number
AU2020245480A1
AU2020245480A1 AU2020245480A AU2020245480A AU2020245480A1 AU 2020245480 A1 AU2020245480 A1 AU 2020245480A1 AU 2020245480 A AU2020245480 A AU 2020245480A AU 2020245480 A AU2020245480 A AU 2020245480A AU 2020245480 A1 AU2020245480 A1 AU 2020245480A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
cancer
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020245480A
Other languages
English (en)
Inventor
Michael D. Bartberger
Justin A. HILF
Oliver C. LOSON
Martina S. MCDERMOTT
Brendan M. O'boyle
Neil A. O'Brien
Corey M. Reeves
Dennis Slamon
Brian M. Stoltz
Steven J. Wittenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
University of California San Diego UCSD
1200 Pharma LLC
Original Assignee
California Institute of Technology
University of California Berkeley
University of California San Diego UCSD
1200 Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology, University of California Berkeley, University of California San Diego UCSD, 1200 Pharma LLC filed Critical California Institute of Technology
Publication of AU2020245480A1 publication Critical patent/AU2020245480A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020245480A 2019-03-25 2020-03-25 PRMT5 inhibitors and uses thereof Abandoned AU2020245480A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962823374P 2019-03-25 2019-03-25
US62/823,374 2019-03-25
US201962874773P 2019-07-16 2019-07-16
US62/874,773 2019-07-16
PCT/US2020/024654 WO2020198323A1 (en) 2019-03-25 2020-03-25 Prmt5 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2020245480A1 true AU2020245480A1 (en) 2021-11-11

Family

ID=72609147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020245480A Abandoned AU2020245480A1 (en) 2019-03-25 2020-03-25 PRMT5 inhibitors and uses thereof

Country Status (12)

Country Link
US (1) US12583859B2 (enExample)
EP (1) EP3947387B1 (enExample)
JP (1) JP7609798B2 (enExample)
KR (1) KR20220023330A (enExample)
CN (1) CN114127072B (enExample)
AU (1) AU2020245480A1 (enExample)
BR (1) BR112021019125A2 (enExample)
CA (1) CA3134779A1 (enExample)
IL (2) IL318073A (enExample)
MX (1) MX2021011524A (enExample)
SG (1) SG11202110272SA (enExample)
WO (1) WO2020198323A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
IL318073A (en) 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
EP4458836A4 (en) * 2021-12-27 2025-05-21 Riken Genesis Co., Ltd. Novel artificial nucleic acid, method for producing same, and use of same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) * 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3939986A1 (en) * 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11059850B2 (en) * 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
IL318073A (en) 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses

Also Published As

Publication number Publication date
EP3947387B1 (en) 2024-10-23
MX2021011524A (es) 2021-12-15
CN114127072A (zh) 2022-03-01
US20220194949A1 (en) 2022-06-23
BR112021019125A2 (pt) 2021-11-30
IL318073A (en) 2025-02-01
CN114127072B (zh) 2024-10-11
JP7609798B2 (ja) 2025-01-07
KR20220023330A (ko) 2022-03-02
EP3947387A4 (en) 2022-11-30
WO2020198323A1 (en) 2020-10-01
SG11202110272SA (en) 2021-10-28
JP2022521818A (ja) 2022-04-12
US12583859B2 (en) 2026-03-24
CA3134779A1 (en) 2020-10-01
EP3947387A1 (en) 2022-02-09
IL286622A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
EP3947387B1 (en) Prmt5 inhibitors and uses thereof
CN114096544B (zh) Kras g12c抑制剂及其用途
US20250136582A1 (en) Select kras g12c inhibitors and uses thereof
WO2022115439A1 (en) Kras g12c inhibitors and uses thereof
CN114072407A (zh) 靶向prmt5的化合物
JP2017178968A (ja) 化合物、その医薬組成物、及び癌治療用のｉｄｈ１突然変異阻害薬としてのその使用
KR20220042127A (ko) 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용
WO2022227987A1 (zh) 杂环类衍生物及其制备方法和用途
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
KR102833011B1 (ko) 푸로[3,4-b]피롤-함유 BTK 억제제
CN117916234A (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
WO2022143533A1 (zh) 喹唑啉衍生物及其在医药上的应用
HK40063243B (en) Prmt5 inhibitors and uses thereof
HK40063243A (en) Prmt5 inhibitors and uses thereof
EP4038072A1 (en) Mcl1 inhibitors and uses thereof
WO2022216945A1 (en) Macrocyclic mcl1 inhibitors and uses thereof
TW202200586A (zh) 靶向prmt5之化合物
WO2022216946A1 (en) Mcl1 inhibitors and uses thereof
CN117486885B (zh) 吡唑并嘧啶类化合物的用途
EP4698531A1 (en) Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof
CN118255714A (zh) 受体酪氨酸激酶抑制剂、其制备方法及其应用
IL321757A (en) Naphthylamide compound, and preparation method therefor and use thereof
CN116239571A (zh) 含有吡唑衍生物结构的化合物
OA19533A (en) Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application